Cynthia Lavoie, PhD, MBA

During her tenure at TVM Capital, Cynthia was responsible for deal making, deal origination and execution and for the management of portfolio companies in the US and Canada. There, she led investments in Kaneq Bioscience, FAAH Pharma, as well as Acer Therapeutics and served on their board of directors. Cynthia joined TVM in 2012 with ten years of investment experience and another ten years in research institutions and life science firms. Prior to TVM, she was with VenGrowth Partners, where her most recent role was as Partner and head of life sciences. She served on the boards of therapeutics and device companies including Cytochroma (sold to Opko Health) and Trillium Therapeutics (NASDAQ: TRIL). Cynthia also had a direct role in the sale of VisualSonics, to SonoSite Inc. (now Fujifilm SonoSite). She started her career as a marketing strategy consultant with Vasogen. Cynthia completed her PhD at McGill University and carried out research at the University of Texas Southwestern Medical Center. She also holds an MBA from the Rotman School of Management.